Holen Sie sich die Stockscreener-App
36.07
2.30%
0.81
Handel nachbörslich:
35.50
-0.57
-1.58%
Schlusskurs vom Vortag:
$35.26
Offen:
$35.3
24-Stunden-Volumen:
2.41M
Relative Volume:
1.12
Marktkapitalisierung:
$6.74B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-9.8552
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
-1.64%
1M Leistung:
-5.13%
6M Leistung:
-12.71%
1J Leistung:
-16.12%
1-Tages-Spanne:
$34.88
$36.24
1-Wochen-Bereich:
$34.00
$36.24
52-Wochen-Spanne:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
36.07 | 6.49B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer - uk.finance.yahoo.com
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
Revolution Medicines’ Earnings Call: Progress Amid Challenges - TipRanks
Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy - MSN
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $56 to $80 - 富途牛牛
Revolution Medicines (RVMD): A High-Risk, High-Reward Biotech Play in the RAS Oncology Space - AInvest
Contradictions Unveiled: RASolute 302 Study Progress and Efficacy Concerns in Latest Earnings Call - AInvest
Earnings call transcript: Revolution Medicines Q2 2025 sees stock dip after earnings miss - Investing.com
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data - Investing.com India
Revolution Medicines August 2025 slides: advancing RAS inhibitor pipeline with promising data By Investing.com - Investing.com South Africa
Revolution Medicines Advances RAS-Targeted Therapies, Reports Q2 Earnings - AInvest
Revolution Medicines Advances RAS-Targeted Therapies - TipRanks
Revolution Medicines Q2 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines shares rise 2.13% after-hours after reporting strong Phase 3 trial progress and $2 billion funding agreement. - AInvest
Transcript : Revolution Medicines, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Revolution Medicines Doubles Down On Losses To Fuel New Drugs - Finimize
Earnings Flash: (RVMD) Revolution Medicines Q2 Loss $1.31 Vs. FactSet Est. $1.12 Loss - MarketScreener
Revolution Medicines Reports Wider Q2 Loss, Receives Breakthrough Therapy Designation for Elironrasib - AInvest
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire
Revolution Medicines Secures FDA Breakthrough Status, $2B Funding for Cancer Trials | RVMD Stock News - Stock Titan
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - The Globe and Mail
Tango (TNGX) Q2 Revenue Drops 52% - The Motley Fool
Revolution Medicines shares rise 2.80% intraday after Tango Therapeutics reported dosing first patient in combination trial with Revolution Medicines RAS(ON) inhibitors. - AInvest
What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings - Yahoo Finance
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Recovery Setup Building in Revolution Medicines Inc. Experts SayLow Risk Equity Screener With Results Shared - metal.it
What analysts say about Revolution Medicines Inc. stockInvest smarter and grow your wealth faster - Jammu Links News
What drives Revolution Medicines Inc. stock priceDiscover high-growth stocks for your portfolio - Jammu Links News
When is Revolution Medicines Inc. stock expected to show significant growthExplosive returns - Jammu Links News
Is it the right time to buy Revolution Medicines Inc. Equity Warrant stockCapitalize on market trends with confidence - Jammu Links News
How does Revolution Medicines Inc. compare to its industry peersSuperior stock growth - Jammu Links News
What is Revolution Medicines Inc. company’s growth strategyUnmatched market gains - Jammu Links News
Is Revolution Medicines Inc. a growth stock or a value stockRapidly growing investment returns - Jammu Links News
Published on: 2025-08-03 19:52:18 - Jammu Links News
Is Revolution Medicines Inc. Equity Warrant a growth stock or a value stockHigh-yield capital appreciation - Jammu Links News
How strong is Revolution Medicines Inc. company’s balance sheetDiscover high-return stocks for your portfolio - Jammu Links News
How many analysts rate Revolution Medicines Inc. Equity Warrant as a “Buy”Harness the power of proven investment plans - Jammu Links News
How volatile is Revolution Medicines Inc. Equity Warrant stock compared to the marketAccelerated earnings growth - Jammu Links News
What is the risk reward ratio of investing in Revolution Medicines Inc. Equity Warrant stockAchieve consistent profits with expert advice - Jammu Links News
Published on: 2025-08-03 11:06:26 - Jammu Links News
What are the latest earnings results for Revolution Medicines Inc. Equity WarrantMarket-leading growth rates - jammulinksnews.com
Is Revolution Medicines Inc. Equity Warrant stock overvalued or undervaluedTriple-digit return opportunities - Jammu Links News
Is Revolution Medicines Inc. a good long term investmentGet exclusive access to professional stock picks - Jammu Links News
What institutional investors are buying Revolution Medicines Inc. Equity Warrant stockDiscover high-return stocks for your portfolio - Jammu Links News
Is Revolution Medicines Inc. stock overvalued or undervaluedMarket-leading profit generation - Jammu Links News
What is the risk reward ratio of investing in Revolution Medicines Inc. stockInvest like a pro with expert recommendations - Jammu Links News
How does Revolution Medicines Inc. Equity Warrant compare to its industry peersGet timely alerts on market movers - Jammu Links News
What are Revolution Medicines Inc. company’s key revenue driversDaily Trading Report For Consistent Profits - Jammu Links News
What is the dividend policy of Revolution Medicines Inc. Equity Warrant stockTop Growth Tips For Consistent Profits - Jammu Links News
Revolution Medicines Announces Q2 2025 Earnings Release and Webcast Schedule - AInvest
When is Revolution Medicines Inc. Equity Warrant stock expected to show significant growth - Jammu Links News
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):